Results of a First-in-Human Phase I Study to Assess the Safety, Tolerability, and Dose Range Finding of a Single Intrathecal Dose of ISIS-SMNRx in Patients with Spinal Muscular Atrophy: PS1 - 1.
- Resource Type
- Academic Journal
- Source
- Annals of Neurology. Oct 01, 2013 74 Suppl 17:S128-S128
- Subject
- Language
- English
- ISSN
- 0364-5134